Clinical Trials Logo

Nose Neoplasms clinical trials

View clinical trials related to Nose Neoplasms.

Filter by:
  • None
  • Page 1

NCT ID: NCT05607888 Recruiting - Clinical trials for Skull Base Neoplasms

Prospective Study of Sinonasal and Skull-base Tumours Management

Sinonasal_Tu
Start date: January 1, 2022
Phase:
Study type: Observational [Patient Registry]

This observational prospective clinical study aims to describe the epidemiology, management and outcome of patients with sinonasal and skull-base pathology (tumours and diseases with malignant clinical characteristics) in a tertiary otorhinolaryngology referral centre. The main questions it aims to answer are: - what is the caseload of patients with the included pathology in our centre - what are the results of management of these cases - what are the epidemiological characteristics of included patients - what is the quality of life of included patients.

NCT ID: NCT02998385 Recruiting - HNSCC Clinical Trials

Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)

SANTAL
Start date: January 20, 2017
Phase: Phase 3
Study type: Interventional

A phase III, multicenter, randomized, open-label, french study comparing: - Arm A : Radiotherapy alone (66 to 70 Gy; 5 fractions/week; 1fraction/day; 2 Gy/fraction) (IMRT or protontherapy) - Arm B: Radiotherapy (66 to 70 Gy; 5 fractions/week; 1fraction/day; 2 Gy/fraction; IMRT or protontherapy) + concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 cycles)

NCT ID: NCT00462735 Completed - Clinical trials for Head and Neck Cancer

Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer

Start date: February 2007
Phase: Phase 2
Study type: Interventional

For advanced head and neck cancer, combined radiation and chemotherapy prevents recurrences and for many patients, improves survival. While combined cisplatin and radiation or cetuximab and radiation is more effective than radiation alone, approximately 50% of these patients will still recur. A more aggressive approach may be needed for these patients to prevent recurrence and death. The strategy of using multiple chemotherapy drugs with radiation given twice a day has been tested at Mount Sinai and University of Chicago. Approximately 80% of patients are cured with this strategy. While cure rates are higher than standard chemotherapy and radiation and the treatment is tolerable, side effects during treatment are common. We propose replacing a chemotherapy drug with a less toxic, targeted therapy called cetuximab. Our goal is to reduce toxicity while maintaining or improving cure rates for these patients.